| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Purity: ≥98%
Baricitinib, (also known as LY3009104 or INCB028050; trade name: Olumiant), is a potent, selective, ATP competitive and orally bioavailable inhibitor of tyrosine-protein kinase JAK1 (Janus kinase) or JAK2 with anti-inflammatory activity. It inhibits JAK1 and JAK2 with IC50s values of 5.9 nM and 5.7 nM, respectively. AS of May 2018, it was approved by FDA for the treatment of rheumatoid arthritis (RA) in the United States. In vitro, it is able to inhibit JAK1 and JAK2 with IC50 values in the low nanomolar range of 5.9 and 5.7 nM, respectively, while it displays low inhibitory activity for JAK3 and moderate activity for TYK2. Baricitinib inhibits intracellular signaling of several proinflammatory cytokines such as IL-6 and IL-23 at concentrations<50 nM. JAK signaling is central to a number of fundamental processes including the generation of RBCs. On Nov 20, 2020, the U.S. Food and Drug Administration also issued an emergency use authorization (EUA) for baricitinib to be used in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). On June 13, 2022, Olumiant (baricitinib) was approved by FDA to treat adult patients with severe alopecia areata, a disorder that often appears as patchy baldness and affects more than 300,000 people in the U.S. each year. Today’s action marks the first FDA approval of a systemic treatment (i.e. treats the entire body rather than a specific location) for alopecia areata.
| ln Vitro |
Cell-based studies demonstrated the potency of baricitinib (INCB028050) as an inhibitor of JAK signaling and function. Baricitinib has IC50 values of 44 nM and 40 nM, respectively, which prevent IL-6-stimulated phosphorylation of canonical substrate STAT3 (pSTAT3) and the subsequent generation of the chemokine MCP-1 in PBMC. INCB028050 also suppresses pSTAT3 activated by IL-23 (IC50=20 nM) in isolated naïve T cells. This suppression stops Th17 cells from producing the two harmful cytokines, IL-17 and IL-22. Th17 cells have an IC50 value of 50 nM and are a subtype of helper T cells with unique inflammatory and pathogenic characteristics. Even at doses up to 10 μM, the structurally similar but ineffective JAK1/2 inhibitors INCB027753 and INCB029843 exhibited no discernible effect in any of these assay systems [1].
|
||
|---|---|---|---|
| ln Vivo |
Over the course of a 2-week treatment period, baricitinib (INCB028050) therapy reduced the rise in hindpaw volume by 50% at 1 mg/kg and >95% at 3 or 10 mg/kg. Given that baseline measurements of paw volume were obtained in animals exhibiting clear illness indications on day 0 of treatment, those exhibiting a notable improvement in swelling may exhibit >100% inhibition [1]. Mice given baricitinib (0.7 mg/kg/day) showed markedly decreased MHC class I and class II expression, decreased CD8 infiltration, and dramatically decreased inflammation (measured by H&E staining). When compared to vehicle control animals, the number of CD8+NKG2D+ cells, which are important effector cells in alopecia areata (AA) illness in both people and mice, is markedly lower in mice treated with baricitinib [2].
|
||
| Animal Protocol |
|
||
| References |
[1]. Fridman JS, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010 May 1;184(9):5298-307.
[2]. Jabbari A, et al. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015 Feb 26;2(4):351-5. [3]. Khan IM, et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration resistance. Int J Obes (Lond). 2015 Nov;39(11):1607-18 |
| Molecular Formula |
C16H17N7O2S
|
|
|---|---|---|
| Molecular Weight |
371.42
|
|
| CAS # |
1187594-09-7
|
|
| Related CAS # |
Baricitinib phosphate;1187595-84-1;Baricitinib-d5;1564241-79-7;Baricitinib-d3;1564242-30-3
|
|
| SMILES |
S(C([H])([H])C([H])([H])[H])(N1C([H])([H])C(C([H])([H])C#N)(C1([H])[H])N1C([H])=C(C2=C3C([H])=C([H])N([H])C3=NC([H])=N2)C([H])=N1)(=O)=O
|
|
| InChi Key |
XUZMWHLSFXCVMG-UHFFFAOYSA-N
|
|
| Chemical Name |
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.73 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.73 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 0.5% CMC+0.25% Tween 80:30mg/mL Solubility in Formulation 5: 2.5 mg/mL (6.73 mM) in 0.5% Methylcellulose/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6924 mL | 13.4618 mL | 26.9237 mL | |
| 5 mM | 0.5385 mL | 2.6924 mL | 5.3847 mL | |
| 10 mM | 0.2692 mL | 1.3462 mL | 2.6924 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04901325 | Recruiting | Drug: Baricitinib | RPyoderma Gangrenosum Skin Diseases |
Oregon Health and Science University | October 2023 | Phase 2 |
| NCT05852171 | Recruiting | Drug: Baricitinib | Mastitis Chronic Idiopathic Granulomatous Mastitis |
First Affiliated Hospital of Zhejiang University |
January 1, 2023 | Phase 2 |
| NCT05074420 | Recruiting | Drug: Baricitinib | Covid19 Corona Virus Infection |
Eli Lilly and Company | December 21, 2021 | Phase 3 |
| NCT06240351 | Not yet recruiting | Drug: Baricitinib 4 MG Oral Tablet | Frontal Fibrosing Alopecia | University of Alabama at Birmingham |
June 1, 2024 | Phase 4 |
Cellular activity of INCB028050.J Immunol.2010 May 1;184(9):5298-307. |
Anti-inflammatory and DMARD activity of once daily INCB028050 in rats with established disease in the adjuvant arthritis model.J Immunol.2010 May 1;184(9):5298-307. |
Suppression of delayed-type hypersensitivity by INCB028050.J Immunol.2010 May 1;184(9):5298-307. |
INCB028050 is efficacious and well tolerated independently of effects on humoral immunity.J Immunol.2010 May 1;184(9):5298-307. |
INCB028050 improves clinical and histologic signs of disease in the murine CIA model. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
